期刊文献+

可溶性CD40在在良恶性胸腔积液鉴别诊断中的价值 被引量:3

The role of soluble CD40 in diagnosis of benign and malignant pleural effusion
原文传递
导出
摘要 目的 探讨中可溶性CD40(sCD40)浓度水平在良恶性胸腔积液鉴别中的价值.方法 回顾性分析我院2016年1月至2017年12月间收治胸腔积液患者共98例,其中良性胸腔积液患者48例,恶性胸腔积液患者50例,采用酶联免疫吸附法(ELISA)检测胸腔积液中sCD40的浓度水平,以受试者工作曲线(ROC)分析可溶性CD40(sCD40)浓度水平在胸腔积液良恶性鉴别中的价值.结果 恶性胸腔积液组中sCD40平均浓度为(248.6±20.8)pg/ml,明显高于良性胸腔积液组[(105.8±19.3)pg/ml],且差异有统计学意义(P<0.05).sCD40诊断恶性胸腔积液的最佳临界值为121.6 pg/ml,特异度、敏感度、准确度分别为81.3%、90.0%、85.7%.相关性分析表明,sCD40表达与年龄正相关(r=0.673,P<0.05),与性别、胸腔积液类型无关(P>0.05).结论 sCD40在恶性胸腔积液中高表达,对良性及恶性胸腔积液的鉴别诊断具有重要价值. Objective To investigate the role of soluble CD40(sCD40)levels in differential diagnosis of benign and malignant pleural effusion.Methods Ninety-eight patients with pleural effusion admitted to our hospital between January 2016 and December 2017 were retrospectively analyzed,including 48 patients with benign and 50 with malignant pleural effusion.Enzyme-linked immunosorbent assay(ELISA)was used to examine the levels of sCD40 in the pleural effusion.Receiver operating curve(ROC)was used to analyze the role of sCD40 concentration levels in distinguishing benign and malignant pleural effusion.Results The mean level of sCD40 in the malignant pleural effusion group was(248.6±20.8)pg/ml,which was significantly higher than that in the benign pleural effusion group[(105.8±19.3)pg/ml],with statistically significant difference(P<0.05).The optimal cut-off value of sCD40 for diagnosing malignant pleural effusion was 121.6 pg/ml.The specificity,sensitivity and accuracy were 81.3%,90.0%and 85.7%,respectively.Correlation analysis showed that the level of sCD40 had a positive correlation with age(r=0.673,P<0.05),and had no correlation with gender and pleural effusion type(P>0.05).Conclusion sCD40 is highly expressed in malignant pleural effusion,which is of great value in the differential diagnosis of benign and malignant pleural effusion.
作者 宋梅梅 徐春华 Song Meimei;Xu Chunhua(Department of Respiratory Medicine,Nanjing Chest Hospital,Nanjing,Jiangsu 210029,China)
出处 《中华生物医学工程杂志》 CAS 2018年第6期438-440,共3页 Chinese Journal of Biomedical Engineering
关键词 可溶性CD40 恶性 胸腔积液 诊断 Soluble CD40 Malignant Pleural effusion Diagnosis
  • 相关文献

参考文献3

二级参考文献29

  • 1张薇,王进,武志芳,胡光.CA_(125)在鉴别良恶性胸腔积液中的应用分析[J].山西医药杂志,2006,35(5):430-431. 被引量:7
  • 2Seemann MD, Bcinert T, Furst H, et al..An evaluation of the tumour markers, carcinoembryonic antigen ( CEA ), cytokeratin marker (CYFRA 21-1 ) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. Lung Cancer, 1999,26 : 149-155.
  • 3Okuno SH, Jett JR. Small cell lung cancer: current therapy and promising new regimens. Oncologist,2002,7:234-238.
  • 4Eigenbrodt E, Basenau D, Hohhusen S, et al. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK ) in human carcinomas. Anticancer Res, 1997,17:3153-3156.
  • 5Oremek GM, Teigelkamp S, Kramer W, et al. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK ) as a tumor marker for renal carcinoma. Anticancer Res, 1999,19:2599-2601.
  • 6Hugo F, Fischer G, Eigenbrodt E. Quantitative detection of tumor M2- PK in serum and plasma. Anticancer Res, 1999,19:2753-2757.
  • 7Riantawan P, Sanqsayan P, Banqpattanasiri K, et al. Limited additive value of pleural fluid carcinoembryonic antigen level in malignantpleural effusion. Respiration,2000,67:24-29.
  • 8Parcel JM, Vires M, Esquerda A, et al. Use of a panel of tumor marker ( carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3,and cytokeratin 19 fragments) in pleural fluid for the differential diagnosisof benign and malignant effusions. Chest, 2004, 126 : 1721-1722.
  • 9Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer,2006,54:1-9.
  • 10American Thoracie Society. Management of malignant pleural effusion.Am J Respir Crit Care Med,2000,162:1987-2001.

共引文献14

同被引文献28

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部